相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Intravenous immunoglobulin protects from experimental allergic bronchopulmonary aspergillosis via a sialylation-dependent mechanism
Silvia Bozza et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Non-Antibody-Secreting Functions of B Cells and Their Contribution to Autoimmune Disease
Andrew Getahun et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 35 (2019)
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Jacques-Eric Gottenberg et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux
Samuel Deshayes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
IL-10-producing regulatory B cells and plasmocytes: Molecular mechanisms and disease relevance
Catia Cerqueira et al.
SEMINARS IN IMMUNOLOGY (2019)
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Danielle M. Gerlag et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Human B-1 Cells and B-1 Cell Antibodies Change With Advancing Age
Nely Rodriguez-Zhurbenko et al.
FRONTIERS IN IMMUNOLOGY (2019)
Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
Eva Schrezenmeier et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Anti-Double-Stranded DNA Isotypes and Anti-C1q Antibody Improve the Diagnostic Specificity of Systemic Lupus Erythematosus
Yu Jia et al.
DISEASE MARKERS (2018)
MIgGGly (mouse IgG glycosylation analysis) - a high-throughput method for studying Fc-linked IgG N-glycosylation in mice with nanoUPLC-ESI-MS
Olga O. Zaytseva et al.
SCIENTIFIC REPORTS (2018)
Antigen Receptor Galaxy: A User-Friendly, Web-Based Tool for Analysis and Visualization of T and B Cell Receptor Repertoire Data
Hanna IJspeert et al.
JOURNAL OF IMMUNOLOGY (2017)
Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?
Michaela Seeling et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mechanisms of Autoantibody-Induced Pathology
Ralf J. Ludwig et al.
FRONTIERS IN IMMUNOLOGY (2017)
Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
Leslie R. Harrold et al.
CLINICAL RHEUMATOLOGY (2017)
MultiQC: summarize analysis results for multiple tools and samples in a single report
Philip Ewels et al.
BIOINFORMATICS (2016)
Natural IgM and the Development of B Cell-Mediated Autoimmune Diseases
Trang T. T. Nguyen et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2016)
Accurate and predictive antibody repertoire profiling by molecular amplification fingerprinting
Tarik A. Khan et al.
SCIENCE ADVANCES (2016)
Effects of allergic diseases and age on the composition of serum IgG glycome in children
Marija Pezer et al.
SCIENTIFIC REPORTS (2016)
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Tobias Alexander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
IgRepertoireConstructor: a novel algorithm for antibody repertoire construction and immunoproteogenomics analysis
Yana Safonova et al.
BIOINFORMATICS (2015)
Symbol Nomenclature for Graphical Representations of Glycans
Ajit Varki et al.
GLYCOBIOLOGY (2015)
Refractory Primary Sjogren Syndrome Successfully Treated With Bortezomib
Juan Jakez-Ocampo et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2015)
Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs
Benjamin M. Fiebiger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus
Steve P. Crampton et al.
DISEASE MODELS & MECHANISMS (2014)
Dendritic cell immunoreceptor: A novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells
Amir H. Massoud et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Type I and type II Fc receptors regulate innate and adaptive immunity
Andrew Pincetic et al.
NATURE IMMUNOLOGY (2014)
A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity
Anja Lux et al.
CELL REPORTS (2014)
Induction of Interleukin-6 Production by Rituximab in Human B Cells
Jonathan D. Jones et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: A comparison using control sera obtained from healthy individuals and patients with multiple medical problems
Ramjai Wichainun
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Inessa Schwab et al.
NATURE REVIEWS IMMUNOLOGY (2013)
B-1 cells in the bone marrow are a significant source of natural IgM
Youn Soo Choi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells
Tom A. Barr et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Natural IgM in Immune Equilibrium and Harnessing Their Therapeutic Potential
Srini V. Kaveri et al.
JOURNAL OF IMMUNOLOGY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Anti-TNF therapy
Nishanthi Thalayasingam et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2011)
CR2+ Marginal Zone B Cell Production of Pathogenic Natural Antibodies Is C3 Independent
Keith M. Woods et al.
JOURNAL OF IMMUNOLOGY (2011)
Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis
Alejandro M. Gomez et al.
JOURNAL OF IMMUNOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Robert M. Anthony et al.
NATURE (2011)
Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo
Anne Baerenwaldt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study
Gro O. Eilertsen et al.
RHEUMATOLOGY (2011)
B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer
David J. DiLillo et al.
YEAR IN IMMUNOLOGY 2 (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
The role of B cells in lupus pathogenesis
Emil Nashi et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice
Karen M. Haas et al.
JOURNAL OF IMMUNOLOGY (2010)
A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus
Lisa C. Willcocks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
Silvia Bosello et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications
Kenneth G. C. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications (vol 10, pg 328, 2010)
Kenneth G. C. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-Specific IgG but Not Autoantibodies in Pemphigus Vulgaris
Angela Nagel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases
M. Ramos-Casals et al.
LUPUS (2009)
Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy
Bjoern Tackenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Treating severe systemic lupus erythematosus with rituximab. An open study
Carlos Abud-Mendoza et al.
REUMATOLOGIA CLINICA (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
Bertrand Godeau et al.
BLOOD (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Not always the bad guys: B cells as regulators of autoimmune pathology
Simon Fillatreau et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice
David J. DiLillo et al.
JOURNAL OF IMMUNOLOGY (2008)
Monocytosis in BXSB mice is due to epistasis between Yaa and the telomeric region of chromosome 1 but does not drive the disease process
N. J. Rogers et al.
GENES AND IMMUNITY (2007)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
Frederic Lavie et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Fc gamma RIIB as a modulator of autoimmune disease susceptibility
Tatyana Tarasenko et al.
AUTOIMMUNITY (2007)
Selective dysregulation of the FcγIIB receptor on memory B cells in SLE
Meggan Mackay et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation
Yoshikatsu Kaneko et al.
SCIENCE (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis
Minoru Hasegawa et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
Therese Vallerskog et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Fc gamma receptors: Old friends and new family members
F Nimmerjahn et al.
IMMUNITY (2006)
B-Cell-targeted therapy for systemic lupus erythematosus
Ramin Sabahi et al.
DRUGS (2006)
FcγRIV:: A novel FcR with distinct IgG subclass specificity
F Nimmerjahn et al.
IMMUNITY (2005)
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice
Y Hamaguchi et al.
JOURNAL OF IMMUNOLOGY (2005)
B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
RJ Looney et al.
ARTHRITIS AND RHEUMATISM (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice
BF Hoyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
JH Anolik et al.
ARTHRITIS AND RHEUMATISM (2004)
Mouse CD20 expression and function
J Uchida et al.
INTERNATIONAL IMMUNOLOGY (2004)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Development of autoantibodies before the clinical onset of systemic lupus erythematosus
MR Arbuckle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
B cell inhibitory receptors and autoimmunity
NR Pritchard et al.
IMMUNOLOGY (2003)
Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome
TD Shanafelt et al.
MAYO CLINIC PROCEEDINGS (2003)
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus - Longitudinal observations
W Stohl et al.
ARTHRITIS AND RHEUMATISM (2003)
An open study of B lymphocyte depletion in systemic lupus erythematosus
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2002)
B cells regulate autoimmunity by provision of IL-10
S Fillatreau et al.
NATURE IMMUNOLOGY (2002)
Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM
M Boes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)